TP53 and neoplasm: In concordance with findings from studies focusing on tumor evolution, our analysis of CNAs clearly identifies NKX3-1, RB1, MAP3K7, CDKN1B, TP53, and ERG copy number losses as strongly enriched CNAs observed in the earliest stages of prostate cancer (Fig. 2).